Skye Bioscience, Inc. (SKYE)
After hours:
| Previous Close | 4.1700 |
| Open | 4.1300 |
| Bid | 4.0700 x 100 |
| Ask | 5.2400 x 200 |
| Day's Range | 4.0700 - 4.2200 |
| 52 Week Range | 1.4400 - 19.4100 |
| Volume | |
| Avg. Volume | 323,447 |
| Market Cap | 124.994M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | 7.77 |
| EPS (TTM) | 0.5300 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
GlobeNewswireSkye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Evercore HealthCONx Conference (Miami)Fireside chat, Tuesday, December 3, 2:10 pm ET + 1x1 meetings Citi Global Healthcare Conference (Miami)Thursday, December 5, 1x1 meetings Piper Sandler Annua
TipRanksSkye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
Skye Bioscience (SKYE) announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial assessing nimacimab, a differentiated CB1 inhibitor, in patients with overweight or obesity. Skye expects to report interim data for the CBeyond Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period. “We are grateful for the amazing motivation and responsiveness shown by our study participants
